
Voices raised on gender-based violence issues at Paisley Town Hall
Gender-based violence was the focus as more than 200 young people attended a special assembly in Paisley Town Hall.
Young people from Renfrewshire and its surrounding areas gathered to hear from Dr Jackson Katz, the creator and co-founder of the Mentors in Violence Prevention (MVP) programme.
It is the first large-scale global prevention and peer mentoring leadership initiative for young people.
Renowned American educator and author Dr Katz addressed those present with Nicola Sykes, a senior education officer from Education Scotland, also on hand to discuss how schools across the country are tackling gender-based violence through the MVP programme.
The Action for Change event was organised by Renfrewshire Council's youth services and children's services, and Education Scotland.
All Renfrewshire schools have established the MVP programme – equipping young people with the skills they need to tackle violence when they see it and provide peer support.
Renfrewshire's young people voted to prevent violence as their top priority at a youth assembly held during the 16 Days of Activism Against Gender-Based Violence campaign.
The Action for Change youth assembly gives young people the chance to have their voices heard and directly influence how the council and its partners support young people to prevent violence.
It's one of many events led by youth services and children's services as part of Young and Equally Safe (YES) in Renfrewshire which aims to tackle gender-based violence, affecting young people, across schools and communities.
Ruaridh Keating, one of Renfrewshire's the YES group leaders, said: 'It's important to talk about gender-based violence so people's voices are heard and it's not a topic that's brushed under the rug; and it's more publicised than it has been in the past.'
Amy-Ellen O'Neill, another YES leader, explained: 'Talking about gender-based violence can help people feel safer to open up about things that have happened to them; especially if everyone talks about it. It raises awareness of the issue.'
Dr Katz said: 'I brag about what Scotland is doing all over the world. Over the last 12 to 13 years, there has been a systematic approach to implementing the MVP programme across the country.
'MVP is a leadership programme for young people to help them have the tools to speak up and challenge and interrupt abusive behaviour.
'We focus on men's violence against women, sexual harassment and assault, domestic and relationship abuse – but it is about all forms of violence.
'The model helps young people become leaders, with young people mentoring younger peers and building their confidence in speaking out.'
Renfrewshire Provost Lorraine Cameron said: 'This event has been a fantastic opportunity for young people to come together and make their voice heard. Real change happens when we listen to what young people have to say.
'Hearing about the work happening in our schools through the Mentors in Violence Prevention and Young and Equally Safe programmes has been inspiring.
'Young people are using their voices and experiences to challenge harmful behaviours, support one another and lead the way in creating safer, more equal communities.
'As a local authority, we are listening to young people and we will build a future free from violence and inequality with young people.
'Our youth services, community learning and development, and schools will continue to work together to support young people across Renfrewshire. The work they do is invaluable.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
3 hours ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.


Daily Record
9 hours ago
- Daily Record
Price of weight loss drug Mounjaro to rise - how much more users will pay
Eli Lilly will raise UK prices for Mounjaro by up to 170 percent to 'address pricing inconsistencies compared with other developed countries, including in Europe' Eli Lilly is sharply increasing the UK price of its weight-loss and diabetes drug Mounjaro, with the cost of some doses set to rise by as much as 170 percent from September. The pharmaceutical company said the move is intended to 'address pricing inconsistencies compared with other developed countries, including in Europe' and ensure a fairer global contribution to funding medical innovation. The most dramatic increase will see the month's supply of the highest doses of the drug jump from £122 to £330. Lower doses will rise by between 45 and 138 percent. However, Lilly stressed that the new list prices will not apply to the NHS, with the company continuing to supply the health service at the existing rate to avoid disrupting patient access. Private healthcare providers, who also prescribe the drug, will be subject to the increase but can negotiate confidential discounts with the company. The move comes against the backdrop of political pressure from the United States, where former president Donald Trump has criticised what he calls 'foreign freeloaders' benefiting from lower drug prices abroad while Americans pay substantially more. In a speech, he singled out obesity treatments, saying a friend in London had bought the 'fat shot drug' for far less than in the US. Research by the Rand Corporation suggests that US drug prices are, on average, almost three times higher than those in many other advanced economies. The pharmaceutical industry has been working to counter the potential threat of a 'most favoured nation' policy, which could peg American prices to those charged internationally. Lilly noted that the UK was one of the first markets where it launched Mounjaro and said its initial priority had been to get the medicine to diabetes patients quickly. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' the company said. Negotiations between drugmakers and the UK government over NHS medicine costs have been tense, with discussions about changes to a clawback tax on drug sales dragging past agreed deadlines. The government's most recent proposals included plans to spend more on medicines, but industry leaders expressed frustration at the lack of detail or clarity on whether this would mean buying more medicines or paying higher prices for existing ones. The National Institute for Health and Care Excellence (NICE) has recommended Mounjaro for up to 3.4 million people in England. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. However, concerns over affordability led to an agreement for a phased rollout, starting with around 250,000 patients who have the highest clinical need over the first three years. NHS England confirmed that the upcoming price changes would not affect how it provides the drug to eligible patients with obesity or diabetes. 'Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers,' it said. The changes place the UK price closer to the European average and come at a time when pharmaceutical companies are increasingly conscious of how international price differences could shape future US policy decisions.


Daily Mirror
10 hours ago
- Daily Mirror
'My baby was born with a fatal illness but a tiny umbrella saved his life'
Little Toby Wornham was diagnosed with an extremely rare life-threatening condition while still in his mother's womb, and was only saved thanks to a pioneering treatment Smiling Toby Wornham looks the picture of health, but he is one of only 50 people in the world known to have an ultra rare heart condition. After his heart defect was detected during mum Jenny Wornham's 20 week scan, his life was saved by a tiny umbrella-like device. Jenny tells The Mirror: 'We feel very lucky. If you met Toby, you wouldn't know what he has been through.' Jenny, 30, who lives in Hampshire with her shipping manager husband Connor, 31, Toby and their eldest son, Arthur, four, says doctors picked up a problem and identified an extra pulmonary blood vessel during her scan, which was diverting blood away from her unborn baby's lungs and putting an impossible strain on his heart. ''It was such a shock when we heard what was wrong with Toby. We had been so thrilled when I had fallen pregnant with him and Arthur was so excited to be getting a sibling. 'But now we were being told that he had a life-threatening issue with his heart and we didn't know what the future was going to hold.' The tot was diagnosed with a condition called pulmonary arteriovenous malformation (PAVM) - an abnormal connection between pulmonary arteries and veins in the lungs. It leads to reduced oxygen levels in the blood and potential blood clots, leading to strokes. It's so rare that the hospital cardiologist told the couple he had only seen one case like it in his career, with fewer than 50 such cases known of across the globe. Miraculously, the condition was only detected because Toby was so wriggly in his mum's womb that the sonographer had to take extra time with the scan - and spotted something wasn't right. 'It was a miracle it was picked up on the scan at all. It would have been life threatening for him if he'd been born without being diagnosed first,' says Jenny, who runs her own art business. Jenny was referred to Southampton General Hospital, where she was monitored until Toby was born in October 2024, weighing 7Ib 10oz. Surgeons were hoping he would get to five days old before he needed lifesaving surgery, but at just three days old his condition deteriorated. Medics operated immediately, inserting a tiny 7mm cocktail umbrella-like device known as an MVP. The appliance is designed to expand within the body, plugging Toby's extra blood vessel, in order to stop blood flow and relieve pressure on his heart. It will remain in him for life. 'He was so tiny, and to see him needing surgery was heartbreaking. When he came back up after the operation it was traumatic - he was covered in tubes and wires.' But after ten days in hospital, Toby was allowed home. He has now made a full recovery - although initially, took aspirin daily to keep his blood thin. Doctors will continue to monitor his progress over the coming months. 'Toby idolises his brother; the two of them have such an incredible bond,' smiled Jenny. 'And now we're looking forward to the future with our miracle boy.'